Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

Bone Therapeutics completes recruitment of its ALLOB®Phase IIA spinal fusion study

  • Read more about Bone Therapeutics completes recruitment of its ALLOB®Phase IIA spinal fusion study

Bone Therapeutics Provides Business Update for the First Quarter of 2016

  • Read more about Bone Therapeutics Provides Business Update for the First Quarter of 2016

Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial

  • Read more about Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial

Bone Therapeutics to enhance value of its severe osteoporosis program by transitioning to allogeneic development

  • Read more about Bone Therapeutics to enhance value of its severe osteoporosis program by transitioning to allogeneic development

Bone Therapeutics celebrates ten years of innovation in bone cell therapy

  • Read more about Bone Therapeutics celebrates ten years of innovation in bone cell therapy

Bone Therapeutics demonstrates superiority of PREOB® in Phase IIB osteonecrosis study presented at EULAR

  • Read more about Bone Therapeutics demonstrates superiority of PREOB® in Phase IIB osteonecrosis study presented at EULAR

Bone Therapeutics Half Year 2016 Results to be announced on 30 August 2016

  • Read more about Bone Therapeutics Half Year 2016 Results to be announced on 30 August 2016

Bone Therapeutics announces H1 results for 2016

  • Read more about Bone Therapeutics announces H1 results for 2016

Bone Therapeutics receives positive ruling on Belgian Patent Income Deduction

  • Read more about Bone Therapeutics receives positive ruling on Belgian Patent Income Deduction

Bone Therapeutics reports positive efficacy data for the ALLOB® Phase IIA spinal fusion trial

  • Read more about Bone Therapeutics reports positive efficacy data for the ALLOB® Phase IIA spinal fusion trial

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions